Pharmacovigilance Guest User Pharmacovigilance Guest User

Introduction to Pharmacovigilance

Fig 1: Drug safety and pharmacovigilance 

Fig 1: Drug safety and pharmacovigilance 

Introduction to pharmacovigilance

 

According to the world health organization, "pharmacovigilance also know as drug safety, is the pharmacological science related to the collection, detection, assessment, monitoring, and prevention of adverse effects of the pharmaceutical drugs"

Aims of pharmacy vigilance are the following

Fig 2: why do we need pharmacovigilance 

Fig 2: why do we need pharmacovigilance 

• Improve patient care about the drugs and keep the patient safe from adverse effects of drug

• Pharmacovigilance keep track of any drastic effect of the drug

• To research the efficacy of the drug and check effects of drugs during trials to the pharmacy and then keep monitoring their effects for many years

• Bring improvement in the public healthcare system by a thorough assessment of drugs effect on the body

• Promote training and knowledge about this field of medicine

• To know the mechanisms of the drug inside the human body

• To encourage safe and rational use of medicines

Fig 4: Phases of drug development 

Fig 4: Phases of drug development 


Objectives of pharmacovigilance

• To properly detect the unknown adverse effect and drug interaction

• Distribution of information about the adverse effect of drugs and drug interactions so that they occur less frequently

• Timely correction of therapeutic errors

• Reevaluation of the risk-benefit balance of medicine, so we can effectively use those drugs for a patient having more benefits and fewer side effects

• Identifications of mechanisms that cause adverse effects of drugs

Fig 3: Stakeholders in pharmacovigilance 

Fig 3: Stakeholders in pharmacovigilance 

There are mainly four stake holders in pharmacovigilance

1- Patient

2- Doctor or pharmacist

3- Marketing authorization holder

4- Regulators such as authorities, committee

Steps of pharmacovigilance

introduction to pharmacovigilance

Fig 5: PV workflow 

Step 1 is the collection of reports about the adverse effect and all adverse reactions of the drugs. All adverse reactions, including serious and unexpected effects, are subjected to expedited reporting.

Step 2 involves receiving the cumulative reports regarding the safety of drugs and sending those reports to all the regulatory authorities.

Step 3 The process of determining the specific adverse effect associated with a specified drug and then comparing this drug with another drug having a similar worse effect.

Step 4 Management of adverse effects of the drugs. Receive information regarding the harmful effects on patients or population and seek a method to minimize these effects.

Pharmacovigilance regulations:

International Conference of Harmonization consists of authorities from India, Europe, and Japan with representatives of the correlating industries, health organization, and WHO as an observer. This conference provides guidelines regarding pharmacovigilance and good drugs. There is stepwise development of instructions. At step four, there is a consensus internationally, and at step 5, an agreement for regulators to introduce the guidelines to legislation.

The principal role of pharmacovigilance is to ensure the safer usage of drugs. But the pressure is increasing on this field to analyze data about the adverse effect, monitor risk more broadly, and accurately reports patient events.

 What information should we report to higher authorities?

• Any information on adverse drug reaction

• lack of efficacy of the drug

• Even when there is no observed adverse effect, report abuse of the drug, effect of overdose, and about drug administration during pregnancy



Read More